Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 317Rectal Neoplasms 235Stomach Neoplasms 209Pancreatic Neoplasms 137Colonic Neoplasms 94Neoplasm Metastasis 60Esophageal Neoplasms 57Neoplasms 40Biliary Tract Neoplasms 39Cholangiocarcinoma 31Carcinoma, Hepatocellular 30Gallbladder Neoplasms 29Breast Neoplasms 28Adenocarcinoma 22Bile Duct Neoplasms 21Locally Advanced Rectal Cancer 20Adenocarcinoma Of Esophagus 20Gastrointestinal Neoplasms 18Liver Neoplasms 17Esophageal Squamous Cell Carcinoma 17Colorectal Cancer Metastatic 15Carcinoma, Non-Small-Cell Lung 12Anus Neoplasms 12Parkinson Disease 4, Autosomal Dominant Lewy Body 11Digestive System Neoplasms 7Carcinoma 7Advanced Gastric Cancer 7Squamous Cell Carcinoma of Head and Neck 6Ovarian Neoplasms 6Klatskin Tumor 6

Interventions

Cetuximab 5Irinotecan 3Gemcitabine 2tivozanib 1neratinib 1lorlatinib 1liposomal doxorubicin 1encorafenib 1binimetinib 1Taxes 1Secretin 1Paclitaxel 1PX-866 1Oxaliplatin 1Lomustine 1Leucovorin 1Fluorouracil 1Doxorubicin 1Carboplatin 1Capecitabine 1CB-839 1CA-19-9 Antigen 1Bevacizumab 1Aspirin 1Albumin-Bound Paclitaxel 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hereditary Sensory and Autonomic Neuropathies × Capecitabine × Gastrointestinal × Clear all
NCT02861300 2024-12-19

CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer

Case Comprehensive Cancer Center

Phase 1/2 Completed
50 enrolled 16 charts
Gastrointestinal

Colonic Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡